{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-024982","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2022-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.622640+00:00","generated_at":"2026-06-23T16:10:05.427592+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Protagenic receives CMC questions from European regulator; expects Q4 2022 trial start","bullets":["Received CMC (Chemistry, Manufacturing and Controls) questions from a European regulatory authority on August 30, 2022.","Company is addressing the questions and currently expects to commence clinical trials in Q4 2022.","Protagenic is also finalizing its US submission for the same trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-024982","json":"https://secwatch.observer/filing/0001493152-22-024982.json","markdown":"https://secwatch.observer/filing/0001493152-22-024982.md","text":"https://secwatch.observer/filing/0001493152-22-024982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315222024982/0001493152-22-024982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315222024982/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T16:10:05.427592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}